Year in review 2012: Critical Care - respiratory infections
نویسندگان
چکیده
منابع مشابه
Year in review 2013: critical care - respiratory infections
Over the last two decades, considerable progress has been made in the understanding of disease mechanisms and infection control strategies related to infections, particularly pneumonia, in critically ill patients. Patient-centered and preventative strategies assume paramount importance in this era of limited health-care resources, in which effective targeted therapy is required to achieve the b...
متن کاملYear in review 2012: Critical Care - cardiology
In this review I discuss key research papers in cardiology and intensive care published in Critical Care during 2012 with related studies published in other journals quoted whenever appropriate. These studies are grouped into the following categories: cardiovascular therapies, mechanical therapies, pathophysiologic mechanisms, hemodynamic monitoring, ultrasound in respiratory failure, microcirc...
متن کاملYear in review 2012: Critical Care - nephrology
We summarize original research in the field of critical care nephrology accepted or published in 2012 in Critical Care and, when considered relevant or directly linked to this research, in other journals. Three main topics have been identified for a rapid overview: acute kidney injury, detailed in some pathogenetic and epidemiological aspects; fluid overload as a predictor of mortality both in ...
متن کاملYear in review 2012: Critical Care -management
Outcomes research plays a key role in defining the effects of medical care in critical care. Last year Critical Care published a number of papers that evaluated patient-centered and policy-relevant outcomes. We present this review article focusing on key reported outcomes associated with severe community-acquired pneumonia, mortality associated with decisions regarding triage to the ICU, and bo...
متن کاملCritical Care Paper Review 2012
Care of patients with sepsis has improved over the last decade. However, in the recent two years, there was no significant progress in the development of a new drug for critically ill patients. In January 2011, it was announced that the worldwide phase 3 randomized trial of a novel anti-Toll-like receptor-4 compound, eritoran tetrasodium, had failed to demonstrate an improvement in the mortalit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Critical Care
سال: 2013
ISSN: 1364-8535
DOI: 10.1186/cc12773